Figure 2.

Forest plot of all-cause 28-day mortality. Forest plot showing the risk ratio in mortality between patients treated with IL-6 receptor antagonist compared with standard of care (SOC). Meta-analysis on 17 randomized controlled studies comprising 8455 patients showed that mortality was significantly 11% lower for patients with COVID-19 treated with tocilizumab compared to SOC and not significant but with lowering 19% mortality in patients treated with sarilumab. Abbreviations: CI, confidence interval; M-H, Mantel-Haenszel random-effects; SOC, standard of care.